retatrutide mechanism of action triple agonist glp-1 gip glucagon Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research Triple Agonism Based Therapies for
Description
Pharmacol Ther (2019) 196:16082
We abstracted all relevant data reported in the included trials, including treatment discontinuation due to adverse events, all-cause death, cardiovascular disease, non-fatal stroke, kidney failure, severe hypoglycaemia, eye disease requiring intervention, health-related quality of life, serious gastrointestinal events, etc
FDA-approved labels were used to determine on- and off-label use
Notably, domain 7 and 10 assessing randomization and blinding were frequently rated as high risk of bias
JCI Insight 7 , e160891 (2022)
